A once over-looked hormone, Amylin is back in the spotlight at the EASD 2024 Annual Meeting!
Join us as experts Thomas Lutz (University of Zurich) and Kirsten Raun (Novo Nordisk) discuss Amylin's exciting potential in treating obesity and type 2 diabetes. From groundbreaking research to innovative Amylin analogues, discover why this hormone might revolutionise metabolic disease treatments. Learn about its unique effects, its synergy with GLP-1, and its promising future.
Stay informed about the latest in diabetes research and innovation with EASDtv!
#EASD2024 #diabetesresearch #obesitytreatment #amylin #glp1 #metabolichealth #diabetescare